The DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.
Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group
Open accessAbstract
The prognosis for patients multiple myeloma (MM) has improved substantially over the past decade with the development of new, more effective chemotherapeutic agents and regimens that possess a high level of anti-tumor activity. In spite of this important progress, however, nearly all MM patients ultimately relapse, even those who experience a complete response to initial therapy. Management of relapsed MM thus represents a vital aspect of the overall care for patients with MM and a critical area of ongoing scientific and clinical research. This comprehensive manuscript from the International Myeloma Working Group provides detailed recommendations on management of relapsed disease, with sections dedicated to diagnostic evaluation, determinants of therapy, and general approach to patients with specific disease characteristics. In addition, the manuscript provides a summary of evidence from clinical trials that have significantly impacted the field, including those evaluating conventional dose therapies, as well as both autologous and allogeneic stem cell transplantation. Specific recommendations are offered for management of first and second relapse, relapsed and refractory disease, and both autologous and allogeneic transplant. Finally, perspective is provided regarding new agents and promising directions in management of relapsed MM.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Those undergoing HCT typically receive a triplet regimen for 3–4 months prior to stem cell collection in order to reduce tumor cell numbers in the bone marrow.”
From Epidemiology, Staging, and Management of Multiple Myeloma (2021) · cites this paper as [34]
Citations
Cites
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Self-citationAntitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
Richardson, P. G. G., Sonneveld, P., Schuster, M. W., Irwin, D. H., Stadtmauer, E. A., Facon, T. T. F., Harousseau, J., Ben‐Yehuda, D., Lonial, S., Goldschmidt, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043445 · Cited by 2,512
Self-citationImproved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A. A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2007) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,241
Self-citationTtal, M. I. A., Ean, J., Dünne, A. A., Toppa, A. S., Ossi, R. G., Hilippe, P., Asassus, C., Acon, T. H. F., Orbert, N., Ayen, C. A. P., et al. (2013) · Cited by 2,161
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
Self-citationHigh-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022340 · Cited by 1,768
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Self-citationCarfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411321 · Cited by 1,332
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–257 of 257
Real-world evidence in diagnostics and treatment of patients with multiple myeloma
Bila, J., Sretenović, A., Marković, O., Stanisavljević, N., Vlaisavljević, N., & Savic, I. (2022) · Medicinski pregled · doi:10.2298/mpns22s1115b · Cited by 1
Advanced practice nurse management in multiple myeloma treated with oral therapy
Sapet, M., Migala, C., Daguenet, É., Collet, P., Boussoualim, K., Thomas, T., Guyotat, D., & Augeul-Meunier, K. (2023) · Bulletin du Cancer · doi:10.1016/j.bulcan.2023.07.010 · Cited by 1
Prognostic value of 18F-FDG PET/CT in patients with relapsed multiple myeloma
Guo, Y.-H., Liu, A., Huang, J., Wang, L., & Yang, M.-F. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05888-5 · Cited by 1
Rosenberg, A. S., Maverakis, E. M., Costello, C. L., Brem, E. A., Wieduwilt, M. J., Luxardi, G., Kaesberg, P. R., Abedi, K., Herbert, S. M., & Tuscano, J. M. (2025) · Blood Neoplasia · doi:10.1016/j.bneo.2025.100067 · Cited by 1
Treatment of Relapsed/Refractory Patients with Multiple Myeloma
Laubach, J. P., Moreau, P., Dimopoulos, M. A., & Richardson, P. G. G. (2017) · Hematologic malignancies · doi:10.1007/978-3-319-25586-6_5 · Cited by 1
Self-citationPrimärtherapie beim Multiplen Myelom
Breitkreutz, I., Raab, M., & Goldschmidt, H. (2018) · Der Internist · doi:10.1007/s00108-018-0527-x · Cited by 2
Special problems in the management of elderly patients with multiple myeloma
Gay, F., & Larocca, A. (2018) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2018.05.027 · Cited by 1
Krishnan, A. Y., Nathwani, N., Amanam, I. U., & Gupta, R. (2019) · Springer eBooks · doi:10.1007/978-3-030-31471-2_5 · Cited by 1
The Value of Anti-angiogenics in Multiple Myeloma Therapy
Moehler, T. M., Hose, D., Andrulis, M., Seckinger, A., & Goldschmidt, H. (2019) · Springer eBooks · doi:10.1007/978-3-319-33673-2_34
Stem Cell Transplantation for Multiple Myeloma
Thanendrarajan, S., & Garg, T. K. (2017) · Stem cell biology and regenerative medicine · doi:10.1007/978-3-319-51833-6_5
The Role of Gremlin1 in Multiple Myeloma
Clark, K. C. (2020) · Adelaide Research & Scholarship (AR&S) (University of Adelaide)
Treatment of relapsed, refractory multiple myeloma: focus on new drugs
Maiolino, Â. (2020) · Hematology Transfusion and Cell Therapy · doi:10.1016/j.htct.2020.09.006
Dimopoulos, M. A., Richardson, P. G. G., & Lonial, S. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.01.005
Self-citationRetractedLudwig, W.-D., & Schwabe, U. (2019) · Springer eBooks · doi:10.1007/978-3-662-59046-1_37
The Value of Anti-Angiogenics in Multiple Myeloma Therapy
Moehler, T. M., Hose, D., Andrulis, M., Seckinger, A., & Goldschmidt, H. (2017) · Springer eBooks · doi:10.1007/978-3-319-31215-6_34-1
(2017) · Asia-Pacific Biotech News · doi:10.1142/s021903031700043x
Advocacies in Support of Rare Disease Patients (Vol. 21, No. 6, Full Issue)
(2017) · Asia-Pacific Biotech News · doi:10.1142/s0219030317001057
Sapelli, J., Filho, J. S., Baiocchi, O., Bachour, P., Abdo, A., Bombonatti, J. F., Loss, S. R., & Langhi, M. M. (2022) · Springer eBooks · doi:10.1007/978-3-030-97687-3_11
Management of Relapsed and Refractory Multiple Myeloma: Recent advances
Rathnam, K., Saju, S. V., & Raju, H. S. (2022) · Indian Journal of Medical and Paediatric Oncology · doi:10.1055/s-0042-1758537 · Cited by 1
Stem Cell Transplant for Plasma Cell Dyscrasias
Sharma, S. K. (2023) · Springer eBooks · doi:10.1007/978-981-19-5802-1_25
Wang, J., Xu, H., Chu, X., & Wang, W.-Y. (2023) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2023.07.016
Silva, G. A. L., Ibraim, M. F., Ferreira, M. A. R., Mangiarini, C. B., Júnior, P. R. H., Rosa, J. D. S., Hernandes, N. N. F., Machado, J. G. L. A., dos Santos, L. L. R., Bastos, R. M., et al. (2023) · doi:10.22533/at.ed.58723161018
ATUAÇÃO DE ACADÊMICOS DE ENFERMAGEM NA PREVENÇÃO DO CÂNCER DE COLO DE ÚTERO
Queiroz, M. S. S., de Araújo, A. M. C., Sousa, C. J. P., de Araújo, C. A., & Morais, A. M. (2023) · doi:10.22533/at.ed.58723161012
Vieira, A. C. D. O., Lima, A. C. P., Araujo, D. D. P., de Almeida, L. B. M., Massena, L. M., dos Santos, L. A. S., Silva, R. D. P., Pereira, T. C., Cinelli, L. P., Junior, C. B., et al. (2023) · doi:10.22533/at.ed.5872316109
SINTOMAS RESPIRATÓRIOS DE PACIENTES PÓS-COVID 19 NO ESTADO DO PARANÁ
da Silva, P. R., FARIA, I. D. M., Ferreira, D. H. C., Posso, E. B., & Brandão, A. (2023) · doi:10.22533/at.ed.58723161014
SINDROME METABOLICA: UMA EPIDEMIA GLOBAL
Filho, L. C. G., Batista, J. O. B., Lopes, W. A. D., Lopes, L. M. D., Stern, M. T., Rocha, R. D. ́. R. R., Amaro, L. L., Mendes, D. S., Filho, S. A. G., de Souza, C. D., et al. (2023) · doi:10.22533/at.ed.58723161011
FISIOTERAPIA NA DISMENORREIA PRIMÁRIA: DA AVALIACAO AO TRATAMENTO
Lopes, J. M., Lehmann, A., Michalczyszyn, L. E., dos Anjos, M. B., Fonseca, V. G., Bini, A. C. D., de Andrade, G. F., Teixeira, J. D. L., Bortolanza, M. C. Z., & Furmann, M. (2023) · doi:10.22533/at.ed.58723161019
INTERVENÇÃO FISIOTERAPÊUTICA NO PÓS OPERATÓRIO DE REVASCULARIZAÇÃO DO MIOCARDIO
Silva, K. S. D., Souza, D. L. D., Neto, A. C. N. G. S., & Nascimento, C. G. R. D. (2023) · doi:10.22533/at.ed.58723161020
AVANÇOS RECENTES EM RINOPLASTIA: TÉCNICAS, TECNOLOGIA E CONSIDERAÇÕES PSICOSSOCIAIS
de Oliveira, G. Q., Silva, M. A. D. S., de Paiva, Á. T., da Cunha, A. C. B. G., dos Santos, V. O., Júnior, P. R. H., Rosa, J. D. S., Hernandes, N. N. F., Bastos, R. M., & Ambrosio, R. D. (2023) · doi:10.22533/at.ed.5872316104
TRANSPLANTE DE PULMÃO COMO ALTERNATIVA TERAPÊUTICA EM PACIENTES COM FIBROSE PULMONAR PÓS COVID-19
Pinto, E. D. O. P., & Vandresen, F. (2023) · doi:10.22533/at.ed.5872316102
SISTEMATIZAÇÃO DA ASSISTÊNCIA DE ENFERMAGEM: CONTEXTO HISTÓRICO DO CUIDADO, METODOLOGIA E TEORIA
Fernandes, F., de Oliveira, M. L., Londero, C. A., Gehlen, M. H., Munhoz, O. L., & Ilha, S. (2023) · doi:10.22533/at.ed.5872316108
Aguiar, M. C. D. S., Cerqueira, U. M., Soares, G. R. D. S., de Siqueira, P. R. A., Nazareth, I. V., dos Santos, S. D., & Ventura, R. B. D. S. C. (2023) · doi:10.22533/at.ed.5872316101
SISTEMAS TRANSDÉRMICOS PARA APLICAÇÃO NA PELE: UMA REVISÃO INTEGRATIVA
Sousa, J. D. P. D. S., Reis, M. S., Veloso, R. P., Carvalho, I. P. S., & Carvalho, A. L. M. (2023) · doi:10.22533/at.ed.5872316106
RETINOBLASTOMA EM CRIANÇAS: UMA REVISÃO ATUALIZADA DA LITERATURA
Silva, L. G. D. O., Leite, N. D. C. C., Barbosa, J. D. R., da Silva, M. L. M., Júnior, P. R. H., Hernandes, N. N. F., & Carvalhedo, F. D. C. B. T. (2023) · doi:10.22533/at.ed.5872316105
A pesquisa em saúde: desafios atuais e perspectivas futuras 7
Cavalcanti, S. A. U. (2023) · doi:10.22533/at.ed.587231610
AVANÇOS NAS TERAPIAS PARA O TRATAMENTO DA INFERTILIDADE FEMININA
Mangiarini, C. B., Silva, G. A. L., Ibraim, M. F., Ferreira, M. A. R., Hernandes, E. L., Cardoso, A. B. C., da Silva, M. V. N., Júnior, P. R. H., Rosa, J. D. S., Hernandes, N. N. F., et al. (2023) · doi:10.22533/at.ed.58723161017
EFEITOS DA TERAPIA ANTI-INFLAMATÓRIA NÃO ESTEROIDAL EM PACIENTES COM DOENÇA RENAL CRÔNICA
Barbosa, B. R., & Moraes, R. (2023) · doi:10.22533/at.ed.58723161015
DESVENDANDO O PANORAMA: PATOLOGIAS PEDIÁTRICAS PROLÍFICAS NA ATENÇÃO PRIMÁRIA ATÉ 2021
de Oliveira, C. M. S., de Almeida, M. C. D. M., Júnior, P. R. H., Hernandes, N. N. F., & Sousa, N. B. E. (2023) · doi:10.22533/at.ed.58723161010
de Souza, A. G. A. S., Fernandes, I. M., Júnior, P. R. H., Hernandes, N. N. F., & Vieira, D. R. (2023) · doi:10.22533/at.ed.5872316107
Braga, C. B., Almeida, M. G. O., de Andrade, F. S. F., Gomes, A. K. M. D. A., de Mesquita, R. S., de Amaral, M. G., & Neto, A. M. D. C. (2023) · doi:10.22533/at.ed.58723161016
AVANÇOS PROMISSORES: NOVAS TERAPIAS NO TRATAMENTO DA LEUCEMIA NA INFÂNCIA: UMA REVISÃO DA LITERATURA
Ibraim, M. F., Ferreira, M. A. R., Mangiarini, C. B., Silva, G. A. L., Júnior, P. R. H., Rosa, J. D. S., Hernandes, N. N. F., Bastos, R. M., & Côrtes, P. P. D. R. (2023) · doi:10.22533/at.ed.5872316103
Nieto, Y. L., Yang, Z., Valdez, B. C., Kundu, S., Bashir, Q., Ramdial, J., Srour, S. A., & Qazilbash, M. H. (2023) · American Journal of Hematology · doi:10.1002/ajh.27168
Nawrocki, S. T., Olea, J., Celi, C. V., Dadrastoussi, H., Wu, K., Tsao-Wei, D. D., Colombo, A., Coffey, M. C., Hernandez, E. F., Chen, X., et al. (2023) · doi:10.1158/1078-0432.c.6982800
Alegre, A. M., Gironella, M., Escalante, F., Bergua, J., Martínez‐Chamorro, C., López, A., González, E., Bárez, A., Somolinos, N., Persona, E. P., et al. (2024) · HemaSphere · doi:10.1002/hem3.81
Gangur, H. A., Trivedi, H., Chamarthy, U., Al-Janadi, A., & Srkalović, G. (2024) · Cancers · doi:10.3390/cancers16223805
Peng, L., Shan, T., Zhou, X., Feng, Z., Qiang, W., Lü, J., He, H., & Du, J. (2025) · OncoTargets and Therapy · doi:10.2147/ott.s516486
Kourelis, T., Ailawadhi, S., Vogl, D. T., Gibson, S. E., Sharik, M. E., Du, M. T., Ames, T. D., Yim, C. Y., Baeck, J., Price, M. R., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2574
Serum ATIC Expression as a Novel Diagnostic and Prognostic Biomarker in Multiple Myeloma Patients
Gu, M., Zheng, Y., Wang, Y., Wang, Q., Wu, J., Xiong, Z., Nong, Y., Huang, C., Li, Z., Luo, J., et al. (2025) · Blood and Lymphatic Cancer Targets and Therapy · doi:10.2147/blctt.s537524
Diaconescu, D. E., Iordan, I., Dumitru, I., ILINESCU, A.-M., Soare, D., Ene, G., & Bumbea, H. (2025) · MAEDICA – a Journal of Clinical Medicine · doi:10.26574/maedica.2025.20.2.422
Baďurová, K., Kapustová, V., Kotulová, J., Brinsa, V., Piherová, L., Janoušek, V., Pohludka, M., Richtář, M., Jelínek, T., Hájek, R., et al. (2026) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-026-00836-7 · Cited by 1
王, 辉. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1641355
Li, X., Chen, M., Kuang, L., Liu, J., 黄蓓晖, & Li, J. (2026) · Cancer Medicine · doi:10.1002/cam4.71911
Yue, Y., Du, W., Miao, Y., Wang, F., Luo, L., Yan, L. P. C., Cao, Y., Qi, Y., Li, K., Liu, Y., et al. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.153126
Cai, Z., Xia, Z., He, A., Dong, Y., Wang, Y., Liao, A., Song, Y., Chen, H., Zuppa, A., Chastain, K. M., et al. (2026) · eJHaem · doi:10.1002/jha2.70340
Metadata
- Authors
- Laubach, J., Garderet, L., Mahindra, A., Gahrton, G., Caers, J., Sezer, O., Voorhees, P., Leleu, X., Johnsen, H. E., Streetly, M., Jurczyszyn, A., Ludwig, H., Mellqvist, U.-H., Chng, W.-J., Pilarski, L., Einsele, H., Hou, J., Turesson, I., Zamagni, E., Chim, C. S., Mazumder, A., Westin, J., Lu, J., Reiman, T., Kristinsson, S., Joshua, D., Roussel, M., O'Gorman, P., Terpos, E., McCarthy, P., Dimopoulos, M., Moreau, P., Orlowski, R. Z., Miguel, J. S., Anderson, K. C., Palumbo, A., Kumar, S., Rajkumar, V, Durie, B., & Richardson, P. G.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Hôpital Saint-Antoine (FR)
- University of California, San Francisco (US)
- Karolinska University Hospital (SE)
- Centre Hospitalier Universitaire de Liège (BE)
- Istanbul Memorial Hospital (TR)
- University of North Carolina at Chapel Hill (US)
- Centre Hospitalier Universitaire de Lille (FR)
- Aalborg University Hospital (DK)
- King's College Hospital (GB)
- Jagiellonian University (PL)
- Wilhelminen Hospital (AT)
- Sahlgrenska University Hospital (SE)
- National University of Singapore (SG)
- University of Alberta (CA)
- Universitätsklinikum Würzburg (DE)
- Second Military Medical University (CN)
- Skåne University Hospital (SE)
- University of Bologna (IT)
- Queen Mary Hospital (CN)
- NYU Langone Health (US)
- Peking University People's Hospital (CN)
- Dalhousie University (CA)
- Royal Prince Alfred Hospital (AU)
- Hôpital Purpan (FR)
- National and Kapodistrian University of Athens (GR)
- Roswell Park Comprehensive Cancer Center (US)
- Nantes Université (FR)
- The University of Texas MD Anderson Cancer Center (US)
- University of Turin (IT)
- Mayo Clinic (US)
- Cedars-Sinai Medical Center (US)
- Corresponding author
- Richardson, P G
- ORCID
- Laubach, J
- Garderet, L
- Caers, J
- Sezer, O
- Voorhees, P
- Leleu, X
- Johnsen, H E
- Streetly, M
- Jurczyszyn, A
- Ludwig, H
- Einsele, H
- Hou, J
- Turesson, I
- Zamagni, E
- Chim, C S
- Mazumder, A
- Reiman, T
- Kristinsson, S
- Roussel, M
- Terpos, E
- McCarthy, P
- Dimopoulos, M
- Moreau, P
- Orlowski, R Z
- Anderson, K C
- Palumbo, A
- Kumar, S
- Durie, B
- Richardson, P G
- Venue
- Leukemia
- Published
- 2015-12-29
- Volume
- 30
- Issue
- 5
- Pages
- 1005-1017
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2216303864
- Cited by
- 258
- References
- 133
- Citations by year
- 2026: 7 · 2025: 15 · 2024: 10 · 2023: 33 · 2022: 24 · 2021: 25 · 2020: 35 · 2019: 29 · 2018: 32 · 2017: 38 · 2016: 10
- FWCI
- 3.99
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Locations
- Leukemia (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion)
- Jagiellonian University Repository (Jagiellonian University) (submittedVersion, other-oa)
- Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion, cc-by-nc-nd)
- The HKU Scholars Hub (University of Hong Kong) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- ORBi (University of Liège) (submittedVersion)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Keywords
- relapsed multiple myeloma, relapsed/refractory multiple myeloma, second relapse, autologous stem cell transplantation, allogeneic stem cell transplantation, conventional-dose chemotherapy, diagnostic assessment, treatment selection
- MeSH terms
- Antineoplastic Agents, Humans, Multiple Myeloma, Recurrence, Salvage Therapy, Practice Guidelines as Topic, Hematopoietic Stem Cell Transplantation, Disease Management
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
